Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$201.99 USD

201.99
3,236,689

+8.81 (4.56%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $202.30 +0.31 (0.15%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BIIB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Biogen Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 1,050 4,893 3,803 2,610 4,476
Receivables 1,664 1,705 1,549 1,914 1,881
Notes Receivable 0 0 0 0 0
Inventories 2,527 1,344 1,352 1,069 804
Other Current Assets 1,618 1,849 1,153 1,295 1,221
Total Current Assets 6,859 9,791 7,857 6,887 8,382
Net Property & Equipment 3,310 3,299 3,416 3,412 3,247
Investments & Advances 745 2,235 2,832 3,671 2,661
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 929 1,226 1,415 1,370 3,232
Intangibles 14,582 7,599 7,982 8,846 9,285
Deposits & Other Assets 0 0 0 0 0
Total Assets 26,845 24,554 23,877 24,619 27,234
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 150 0 999 0 1,496
Accounts Payable 403 492 589 455 531
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 2,624 2,521 2,535 3,145 2,766
Income Taxes Payable 257 260 175 142 71
Other Current Liabilities 0 0 0 0 0
Total Current Liabilities 3,434 3,273 4,298 3,742 4,864
Mortgages 0 0 0 0 0
Deferred Taxes/Income 642 335 695 1,033 2,811
Convertible Debt 0 0 0 0 0
Long-Term Debt 6,788 6,281 6,274 7,426 4,459
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 781 944 1,321 1,330 1,349
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 12,045 11,166 12,918 13,933 13,895
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 303 73 68 0 0
Retained Earnings 17,628 16,467 13,912 13,976 16,455
Other Equity -154 -174 -43 -313 -139
Treasury Stock 2,977 2,977 2,977 2,977 2,977
Total Shareholder's Equity 14,799 13,388 10,960 10,686 13,339
Total Liabilities & Shareholder's Equity 26,845 24,554 23,877 24,619 27,234
Total Common Equity 14,799 13,388 10,960 10,686 13,339
Shares Outstanding 144.90 144.00 146.80 153.80 180.40
Book Value Per Share 102.14 92.98 74.66 69.48 73.94

Fiscal Year End for Biogen Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 1,050 2,288 6,078 5,041
Receivables NA 1,664 1,781 1,686 1,634
Notes Receivable NA 0 0 0 0
Inventories NA 2,527 2,982 1,334 1,281
Other Current Assets NA 1,618 1,402 1,334 1,806
Total Current Assets NA 6,859 8,454 10,432 9,763
Net Property & Equipment NA 3,310 3,302 3,307 3,301
Investments & Advances NA 745 755 2,313 2,359
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 929 1,070 1,208 1,212
Intangibles NA 14,582 14,152 7,530 7,565
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 26,845 28,193 25,157 24,598
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 150 500 0 0
Accounts Payable NA 403 440 445 491
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 2,624 3,838 2,481 2,288
Income Taxes Payable NA 257 244 260 236
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 3,434 5,022 3,187 3,015
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 642 728 144 251
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 6,788 6,786 6,285 6,283
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 748 777 936
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 12,045 13,714 10,696 10,811
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 303 242 171 91
Retained Earnings NA 17,628 17,378 17,446 16,854
Other Equity NA -154 -163 -179 -182
Treasury Stock NA 2,977 2,977 2,977 2,977
Total Shareholder's Equity NA 14,799 14,480 14,461 13,787
Total Liabilities & Shareholder's Equity NA 26,845 28,193 25,157 24,598
Total Common Equity 0 14,799 14,480 14,461 13,787
Shares Outstanding 145.30 144.90 144.80 144.80 144.70
Book Value Per Share 0.00 102.14 100.00 99.87 95.28